Ensysce Biosciences Announces IRB Approval Of Key Study Protocol
Portfolio Pulse from Happy Mohamed
Ensysce Biosciences (NASDAQ:ENSC) has received approval from the Investigational Review Board for the PF614-201 protocol, a study designed to confirm the time of onset for pain relief by PF614. The study is a key step towards the full Phase 3 evaluation of PF614, a chemically modified opioid product. The company believes that PF614's features, including its bioequivalence to OxyContin and reduced abuse potential, will make it a game changer for the treatment of severe pain.
August 08, 2023 | 12:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ensysce Biosciences has received approval for a key study protocol of PF614, a chemically modified opioid product. This is a significant step towards the full Phase 3 evaluation of PF614, which the company believes will be a game changer for severe pain treatment.
The approval of the study protocol is a significant milestone for Ensysce Biosciences as it brings the company closer to the full Phase 3 evaluation of PF614. The company's belief that PF614 will be a game changer for severe pain treatment suggests a positive outlook for the product and the company. This could potentially lead to increased investor interest and a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100